Table 1.

Genetic abnormalities in AML

Type	Biomarker	Fusion protein/role	References
Rearrangements	t(8;21) (q22;q22.1)	AML1-ETO or RUNX1-CBFA2T1	[616]
	inv(16) (p13.1q22) or t(16;16)(p13.1;q22)	CBFB-MYH11	[617]
	t(15;17) (q22;q12)	PML-RARA	[618]
	t(6;9) (p23;q24)	DEK-NUp214	[619]
	inv(3) (q21.3q26.2) or t(3;3) (q21.3;q26.2)	GATA2-MECOM	[620]
	t(1;22) (p13.3;q13.3)	RBM15/MKL1	[621]
	t(9;22) (q43;q11)	BCR-ABL1	[622]
	t(6;11) (q27;q23)	MLL-AF6	[623]
	t(9;11) (p22;q23)	MLL-AF9	[624]
	t(9;11) (p21.3;q23.3)	MLLT3-KMT2A	[625]
	t(6;9) (p23;q34)	DEK-NUp214	[619]
	t(3;8) (q26.2;q24)	MECOM-MYC	[609]
	t(5;11) (q35;p15.5)	NUP98-NSD1	[626]
Mutations	FLT3, KRAS, NRAS, KIT, PTPN11, NF1	Signaling mediators	[627]
	DNMT3A, IDH1/2, TET2, ASXL1, EZH2, MLL/KMT2A	Epigenetic mediators	[627]
	CEBPA, RUNX1, GATA2	Transcription factors	[628]
	TP53	Tumor suppressing factor	[629]
	SRSF2, U2AF1, SF3B1, ZRSR2, RBM25	Spliceosome complex	[630]
	NPM1	Nucleophosmin	[631]
	RAD21, STAG1, STAG2, SMC1A, SMC3	Cohesin complex	[632]
	MYC	Proto-oncogene	[633]